In an effort to advance personalized medicine, the Icahn School of Medicine at Mount Sinai and Exosome Diagnostics have entered a five-year collaboration for the development of real-time nucleic acid-based body-fluid diagnostics. The agreement will allow Exosome and Mount Sinai to establish targeted research and biomarker discovery programs in oncology, inflammation, and other disease areas.
Exosome will provide technical and development support to Mount Sinai researchers along with early access to proprietary technology products upgrades. The company plans to pursue commercial development and FDA review of successful validations for in vitro diagnostics.
Mount Sinai’s clinical investigators will use their expertise to develop clinical study programs in areas of unmet medical needs by taking advantage of Exosome’s technology that has the ability to extract high-quality RNA from blood, urine, and cerebrospinal fluid.
Under the agreement, Mount Sinai will retain rights to molecular biomarkers associated with disease progression and drug response and Exosome will retain commercial development rights for molecular in vitro diagnostic products.
This deal follows Exosome’s partnership with QIAGEN in July to develop and commercialize co-branded kit products for the capture and processing of RNA and DNA from biofluid exosomes and other microvesicles.